Century Therapeutics adds director, sets 2026 trial timelines

Century Therapeutics adds independent director Joseph Truitt to its board while reiterating 2026 milestones for CNTY-813 IND submission and CNTY-308 clinical entry.

Rhea-AI Filing Summary

Century Therapeutics, Inc. (IPSC) expanded its Board of Directors from six to seven members and appointed Joseph Truitt as a Class I director effective September 9, 2026, with a term running to the 2028 annual stockholders’ meeting. Truitt will also serve on the Compensation Committee and has been deemed an independent director under Nasdaq rules.

For his board service, Truitt will receive an initial option to purchase 148,000 shares of common stock vesting in equal monthly installments over 36 months, plus an annual cash retainer of $40,000, under Century’s existing non‑employee director compensation program. Century highlighted continued progress of its pipeline, stating that CNTY‑813 remains on track for an IND submission in the fourth quarter of 2026 and that CNTY‑308 is anticipated to enter the clinic in 2026, both leveraging its Allo‑Evasion™ 5.0 platform.

8-K Event Classification

3 items: 5.02, 7.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Initial option grant: 148,000 shares Annual board cash retainer: $40,000 Option vesting period: 36 months +4 more

7 metrics

Initial option grant 148,000 shares Non‑employee director stock option granted to Joseph Truitt, vesting over 36 months

Annual board cash retainer $40,000 Cash compensation for Joseph Truitt’s service as a Century Therapeutics director

Option vesting period 36 months Monthly vesting schedule for Joseph Truitt’s initial stock option grant

Board size after appointment 7 directors Century Therapeutics increased its board from six to seven members

Director age 62 years Age of newly appointed director Joseph Truitt

CNTY-813 IND timing Q4 2026 Targeted timing for CNTY‑813 IND submission

CNTY-308 clinical entry 2026 Anticipated year CNTY‑308 will enter the clinic

Key Terms

IND submission, pre-IND meeting, Allo-Evasion™ 5.0, iPSC-derived cell therapies, +2 more

6 terms

IND submission regulatory

"CNTY-813 … remains on track for an IND submission in the fourth quarter of 2026"

An IND submission is an application a drug developer files with a regulatory authority (for example, the U.S. Food and Drug Administration) asking permission to start testing a new medicine in humans. It shows the company’s lab and safety data and a plan for clinical studies; for investors, an accepted IND is like a green light to move from research to trials, reducing development risk and unlocking value milestones.

pre-IND meeting regulatory

"following a pre-IND meeting with the FDA that yielded alignment"

A pre‑IND meeting is a planned discussion between a drug or biologic developer and a regulator before the company files an Investigational New Drug (IND) application to begin human testing. Think of it as a rehearsal where the regulator reviews the developer’s testing plan, highlights data or study design gaps, and signals what evidence will be needed; for investors, the meeting can reduce regulatory uncertainty, speed timelines, and lower the risk of costly delays or extra studies.

Allo-Evasion™ 5.0 technical

"Both programs are engineered with Century’s industry-leading Allo-Evasion™ 5.0 platform"

iPSC-derived cell therapies medical

"a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies"

Cells created by reprogramming ordinary adult cells back to a stem-cell–like state and then turning them into specific cell types for therapy, such as heart, nerve, or immune cells. They matter to investors because they promise a way to replace or repair damaged tissue across many diseases, and a company’s progress with clinical results, manufacturing scale-up, regulatory approval, and patents can materially affect its value—think of turning versatile raw clay into many different manufactured products.

indemnification agreement regulatory

"The Company entered into an indemnification agreement with Mr. Truitt"

An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.

clinical-stage biotechnology company medical

"iECURE, Inc., a clinical-stage biotechnology company advancing genome-editing therapies"

FAQ

What board change did Century Therapeutics (IPSC) announce on September 9, 2026?

Century Therapeutics’ board increased in size from six to seven directors and appointed Joseph Truitt as a Class I director effective September 9, 2026, with a term expiring at the 2028 Annual Meeting of Stockholders, subject to standard director tenure conditions.

How will Joseph Truitt be compensated as a director of Century Therapeutics (IPSC)?

Joseph Truitt will receive an initial option to purchase 148,000 shares of Century’s common stock vesting over 36 months, plus an annual cash retainer of $40,000, all under the company’s Non‑Employee Director Compensation Policy.

What is Joseph Truitt’s background relevant to Century Therapeutics (IPSC)?

Joseph Truitt is Chief Executive Officer of iECURE, Inc. and Chairman of Larimar Therapeutics, with prior CEO roles at Achillion Pharmaceuticals and BioSpecifics Technologies, and earlier commercial and operational roles at several biopharmaceutical companies.

What development timeline did Century Therapeutics (IPSC) give for CNTY-813?

Century stated that CNTY‑813, an iPSC‑derived islet replacement therapy for type 1 diabetes, remains on track for an IND submission in the fourth quarter of 2026, following a pre‑IND FDA meeting that provided alignment on nonclinical data, manufacturing strategy, and Phase 1/2 trial design.

When is CNTY-308 from Century Therapeutics (IPSC) expected to enter the clinic?

Century indicated that CNTY‑308, a CD19‑targeted CD4+/CD8+ αβ CAR‑iT cell therapy for B‑cell‑mediated diseases, is anticipated to enter the clinic in 2026, and that it is engineered with the company’s Allo‑Evasion™ 5.0 platform.

Is Joseph Truitt considered independent under Nasdaq rules at Century Therapeutics (IPSC)?

Yes. Century’s Board determined that Joseph Truitt is an independent director under the applicable Nasdaq listing rules, and there are no family relationships or related‑party transactions requiring disclosure in connection with his appointment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/09/2026 - 04:11 PM Accepted by SEC EDGAR 09/09/2026 - 04:10 PM Learn about SEC filing dates

false 0001850119 0001850119 2026-09-09 2026-09-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2026

Century Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40498		84-2040295
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

25 North 38th Street, 12th Floor Philadelphia, Pennsylvania		19104
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (267) 817-5790

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Exchange on Which Registered
Common Stock, par value $0.0001 per share		IPSC		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On September 9, 2026, the Board of Directors (the “Board”) of Century Therapeutics, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from six to seven directors and appointed Mr. Joseph Truitt as a member of the Board, effective as of September 9, 2026 (the “Effective Date”). Mr. Truitt will serve as a Class I director with a term expiring at the 2028 Annual Meeting of Stockholders, or until his successor is duly elected and qualified or until his earlier resignation, death or removal. Mr. Truitt will serve as a member of the Compensation Committee of the Board.

Mr. Truitt, 62, currently serves as Chief Executive Officer of iECURE, Inc., a gene editing company, a role he has held since March 2021. Since May 2020, Mr. Truitt has served as a member of the board of directors of Larimar Therapeutics, Inc. (Nasdaq: LRMR). Mr. Truitt has also served as a director of Code Biotherapeutics, Inc., a gene therapy development company, since December 2020. From May 2018 until April 2020, Mr. Truitt served as President, Chief Executive Officer and member of the board of directors of Achillion Pharmaceuticals, Inc. (“Achillion”, formerly Nasdaq: ACHN), a clinical-stage biopharmaceutical company developing small molecule drug therapies for immune system disorders, which was acquired by Alexion Pharmaceuticals, Inc., a global biopharmaceutical company, in January 2020. From April 2020 through December 2020, Mr. Truitt served as Chief Executive Officer of BioSpecifics Technologies Corp. (formerly Nasdaq: BSTC), a biopharmaceutical company that develops collagenase-based therapies, which was acquired by Endo International plc in December 2020. Before joining Achillion, from July 2006 to December 2008, Mr. Truitt served as Vice President, Business Development and Product Strategy of Lev Pharmaceuticals, Inc. and, from 2000 to 2006, he served as Vice President, Sales and Operations of Johnson & Johnson – OraPharma, Inc. Prior to this, Mr. Truitt spent nine years at TAP Pharmaceuticals Inc. in a variety of sales and marketing roles before a two-year role as a consultant at IMS Health Inc. Mr. Truitt received his B.S. in Marketing from La Salle University and his M.B.A. from St. Joseph’s University in Pharmaceutical Marketing. Mr. Truitt previously was a Captain in the United States Marine Corps.

Mr. Truitt will be compensated for his service as a non-employee director pursuant to the Company’s Non-Employee Director Compensation Policy. Mr. Truitt will receive an initial option award to purchase 148,000 shares of the Company’s common stock pursuant to the Company’s 2021 Equity Incentive Plan (the “Initial Option Grant”). The Initial Option Grant shall vest in equal monthly installments over a period of 36 months following the Effective Date, subject to Mr. Truitt’s continued service with the Company. Mr. Truitt is also entitled to receive an annual cash retainer of $40,000 as a member of the Board. The Company entered into an indemnification agreement with Mr. Truitt in substantially the same form as those entered into with the other directors of the Company.

The Board has determined that Mr. Truitt is an independent director under the applicable Nasdaq listing rules. There are no family relationships between Mr. Truitt and any of the directors or executive officers of the Company, and there are no transactions in which Mr. Truitt has a direct or indirect material interest requiring disclosure under Item 404(a) of Regulation S-K. There is no arrangement or understanding between Mr. Truitt and any other person pursuant to which Mr. Truitt was selected as a director of the Company.

Item 7.01 Regulation FD Disclosure

On September 9, 2026, the Company issued a press release announcing the appointment to the Board as discussed above. The full text of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference to such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Document
99.1		Press Release of Century Therapeutics, Inc., dated September 9, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CENTURY THERAPEUTICS, INC.
By:	/s/ Brent Pfeiffenberger, Pharm.D., M.B.A.
Name:	Brent Pfeiffenberger, Pharm.D., M.B.A.
Title:	President, Chief Executive Officer and Chairman of the Board of Directors

Date: September 9, 2026

Exhibit 99.1

Century Therapeutics Appoints Joseph Truitt to Board of Directors

PHILADELPHIA, September 9, 2026 - Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors.

Truitt currently serves as Chief Executive Officer and a member of the Board of Directors of iECURE, Inc., a clinical-stage biotechnology company advancing genome-editing therapies for rare, life-threatening genetic diseases. He is Chairman of the Board of Larimar Therapeutics (NASDAQ: LRMR) and a member of the Board of Directors of Code Biotherapeutics. Truitt previously served as Chief Executive Officer of BioSpecifics Technologies Corp. until its acquisition by Endo International plc in December 2020. Prior to BioSpecifics, Truitt spent more than a decade at Achillion Pharmaceuticals, where he held positions of increasing responsibility, including Chief Commercial Officer, Chief Operating Officer and Chief Executive Officer, before the company's acquisition by Alexion Pharmaceuticals in January 2020.

Truitt served as a Captain in the United States Marine Corps. He holds an MBA from Saint Joseph's University and a BS from La Salle University.

“Joe brings a rare combination of commercial leadership and global operational discipline to our board, having built and scaled multiple biotechnology organizations through periods of significant growth and transition,” said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. “As we advance CNTY-813 toward IND submission and CNTY-308 toward clinical entry this year, his experience building teams and infrastructure across geographies will be a valuable resource for Century.”

The appointment comes as Century advances two programs toward key milestones. CNTY-813, an iPSC-derived islet replacement therapy for T1D, remains on track for an IND submission in the fourth quarter of 2026, following a pre-IND meeting with the FDA that yielded alignment on the nonclinical data package, manufacturing strategy, and proposed Phase 1/2 trial design.

CNTY-308, a CD19-targeted CD4+/CD8+ αβ CAR-iT cell therapy for B-cell-mediated diseases, is anticipated to enter the clinic in 2026. Both programs are engineered with Century’s industry-leading Allo-Evasion™ 5.0 platform.

About Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is a biotechnology company advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune diseases, including type 1 diabetes, and cancer. Century’s therapies are derived from its iPSC cell foundry and leverage its novel immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.

Forward-looking statements

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements about our timing and expectations regarding our preclinical and clinical development programs, including planned development of CNTY-813 and CNTY-308, therapeutic potential and market opportunity, ongoing and planned regulatory submissions and interactions, the achievement of developmental milestones, corporate strategies, and anticipated data readouts, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our ability to meet development milestones on anticipated timelines; uncertainties inherent in the results of preliminary data, and pre-clinical studies, which may not be predictive of final results or the results of clinical trials; our ability to obtain clearance of our future IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of geopolitical issues, trade disputes and tariffs, banking instability and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; our ability to recruit and maintain key members of management and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements.

Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For more information:

Century Therapeutics

Douglas Carr

Senior Vice President, Finance

LifeSci Advisors, LLC

Corey Davis, Ph.D.

212-915-2577

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 12.4 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB